Portal de Periódicos da CAPES

The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1.

1987; Springer Nature; Volume: 6; Issue: 12 Linguagem: Inglês

10.1002/j.1460-2075.1987.tb02710.x

1460-2075

Michael Emerman, M. Guyader, Luc Montagnier, David Baltimore, Mark A. Muesing,

Animal Disease Management and Epidemiology

Research Article1 December 1987free access The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. M. Emerman M. Emerman Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author M. Guyader M. Guyader Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author L. Montagnier L. Montagnier Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author D. Baltimore D. Baltimore Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author M. A. Muesing M. A. Muesing Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author M. Emerman M. Emerman Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author M. Guyader M. Guyader Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author L. Montagnier L. Montagnier Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author D. Baltimore D. Baltimore Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author M. A. Muesing M. A. Muesing Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. Search for more papers by this author Author Information M. Emerman1, M. Guyader1, L. Montagnier1, D. Baltimore1 and M. A. Muesing1 1Unité d'Oncologie Viral (CNRS UA 1157), Institut Pasteur, Paris, France. The EMBO Journal (1987)6:3755-3760https://doi.org/10.1002/j.1460-2075.1987.tb02710.x PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info The recently described human immunodeficiency virus type 2 (HIV2) is significantly divergent in sequence from the more frequently isolated human immunodeficiency virus type 1 (HIV1). Both HIV1 and HIV2 encode a transactivator that is capable of strongly stimulating expression directed by the viral long terminal repeat (LTR). Here, we define the region of the HIV2 genome encoding the transactivator and show that the specificity of the transactivator differs from that of HIV1. By deletion analysis of the HIV2-LTR, we show that both HIV1 and HIV2 transactivators require sequences within 35 to 53 bp downstream of the start of transcription. However, in order to stimulate expression at full efficiency, the HIV2 transactivator further requires sequences unique to the HIV2-LTR between nucleotides +53 and +99. Hence, HIV2 poorly transactivates the LTR of HIV1, while two divergent isolates of HIV1 will efficiently transactivate the LTR of either HIV1 or HIV2. Nonetheless, in vivo competition between the transactivators of HIV1 and HIV2 suggests that they use a common mechanism. Previous ArticleNext Article Volume 6Issue 121 December 1987In this issue RelatedDetailsLoading ...